{"id":74061,"date":"2026-05-04T00:31:15","date_gmt":"2026-05-04T00:31:15","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/74061\/"},"modified":"2026-05-04T00:31:15","modified_gmt":"2026-05-04T00:31:15","slug":"novo-rebrands-diabetes-pill-as-ozempic-to-tap-blockbuster-name-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/74061\/","title":{"rendered":"Novo Rebrands Diabetes Pill as Ozempic to Tap Blockbuster Name"},"content":{"rendered":"<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">Novo Nordisk A\/S is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the brand recognition of one of the world\u2019s best-selling drugs. <\/p>\n<p class=\"ArticleBodyText_articleBodyContent__17wqE typography_articleBody___5jDr\" data-component=\"paragraph\">The Danish drugmaker will start selling Ozempic pills in doses of 1.5 milligram, 4 mg and 9 mg to adults from Monday through more than 70,000 pharmacies across the US, according to a statement Friday. <\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk A\/S is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid&hellip;\n","protected":false},"author":2,"featured_media":74062,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[691,16167,71,1567,2016,39896,730,272,13578,21306,39895,38700],"class_list":{"0":"post-74061","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-drugs","9":"tag-eli-lilly-co","10":"tag-europe","11":"tag-food-and-drug-administration","12":"tag-healthcare","13":"tag-industrials","14":"tag-industries","15":"tag-novo-nordisk","16":"tag-novo-nordisk-a-s-b","17":"tag-pharmaceutical","18":"tag-tablet","19":"tag-telemedicine"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116513491131664937","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/74061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=74061"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/74061\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/74062"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=74061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=74061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=74061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}